{"id":"NCT04467840","sponsor":"RedHill Biopharma Limited","briefTitle":"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","officialTitle":"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-08-21","primaryCompletion":"2021-07-18","completion":"2021-07-18","firstPosted":"2020-07-13","resultsPosted":"2023-10-19","lastUpdate":"2025-07-31"},"enrollment":475,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["COVID-19","Lung Infection"],"interventions":[{"type":"DRUG","name":"Opaganib","otherNames":["Yeliva","ABC294640"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Opaganib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A phase 2/3 multi-center randomized, double-blind, parallel arm, placebo- controlled study in Adult Subjects Hospitalized with Severe SARS-CoV-2 Positive Pneumonia to determine the potential of opaganib to improve and/or stabilize the clinical status of the patient.","primaryOutcome":{"measure":"Supplemental Oxygen Requirement","timeFrame":"14 days maintained up to 42 days","effectByArm":[{"arm":"Opaganib","deltaMin":139,"sd":null},{"arm":"Placebo","deltaMin":132,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.391"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":57,"countries":["United States","Brazil","Colombia","Israel","Italy","Mexico","Peru","Poland","Russia","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":52,"n":230},"commonTop":["Constipation","Alanine aminotransferase increased","Insomnia","Hyperkalaemia","Nausea"]}}